Suven Life Sciences Ltd presenting key Scientific and Baseline Characteristic Data of Samelisant (SUVN-G3031) Phase-2 Study in Patients with Narcolepsy at the SLEEP-2022 Conference

Suven Life Sciences presenting two posters at SLEEP-2022 conference, the 36th Annual meeting of the Associated Professional Sleep Societies (APSS, AAS and SRS) being held at Charlotte, North Carolina, USA during 4-8th June 2022.

Accepted presentations:
0624/130: Samelisant (SUVN-G3031), Baseline Characteristics from a Phase-2 Study Evaluating Efficacy and Safety in Patients with Narcolepsy.

0265/045: Samelisant (SUVN-G3031), a Histamine H3 Receptor Inverse Agonist in Animal Models of Narcolepsy.

Samelisant (SUVN-G3031) is currently in Phase2 proof-of-concept (POC) clinical study evaluating efficacy and safety in patients with Narcolepsy (both type-1 and type-2) at various clinical sites both in USA and in Canada. About 65% of targeted patients have been randomized. The Baseline characteristics are consistent with the general narcolepsy population and comparable with other narcolepsy clinical studies. DSMB recommended the study to continue, as there are no safety concerns. Study to continue to enroll the remaining 35% patients as originally planned. Data readout from this study is expected during Q1/Q2 2023.

Samelisant is a potent and selective H3R inverse agonist. Samelisant showed wake-promoting and anticataplectic effects in orexin knockout mice suggesting its potential therapeutic utility in the treatment of excessive daytime sleepiness and cataplexy associated with narcolepsy. Safety and tolerability studies in animals and healthy humans suggested a favorable risk/benefit profile.

Disclaimer and Risk Statement:
Any information on Suven Intellectual Properties, Grant of Patents and Publications related to IP/Patents provided herewith is on as-is-where-is basis and all of the statements, expectations and assumptions, including expectations and assumptions, if any, contained in this update may be forward-looking that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances will differ from the assumptions on which such statements are based. Suven may not undertake to update any forward-looking statements that may be made from time to time